Changes to This Summary (08/02/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Motzer et al. as reference 30. Revised text to state that the primary endpoint was progression-free survival (PFS), and the data were analyzed when disease in 88% of the axitinib patients and 90% of the sorafenib patients had progressed, while 58% and 59%, respectively, had died.
Revised text to state that median PFS was 8.3 months for axitinib and 5.7 months for sorafenib, and median overall survival (OS) was 20.1 months with axitinib versus 19.2 months with sorafenib; however, the largest benefit was seen in patients who received cytokines as first-line therapy and whose median PFS was 12.2 months with axitinib compared with 8.2 months with sorafenib, while median overall survival was 29.4 months with axitinib compared with 27.8 months with sorafenib. Also added that in contrast, in patients who had previously received sunitinib, axitinib was associated with a 2.1-month increase in PFS compared with sorafenib, but median OS was nearly identical: 15.2 months with axitinib compared with 16.5 months with sorafenib.
Revised text to state that comparing the toxicity of the axitinib and sorafenib regimens is complicated.
Added text to include axitinib on the list of single or combination therapies for which there are ongoing clinical trials to which patients might be directed.
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.